Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 13;13(5):R87.
doi: 10.1186/bcr2944.

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study

Affiliations

Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study

Harri Sihto et al. Breast Cancer Res. .

Abstract

Introduction: Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein expression pattern of the primary tumor may influence the first distant metastasis site.

Methods: We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue. Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B, HER2+ enriched, basal-like or non-expressor subtypes.

Results: A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1, those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5) and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and infrequently ER and PgR.

Conclusions: Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain body sites. Several primary tumor proteins were associated with homing of breast cancer cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient inclusion in the study.
Figure 2
Figure 2
Associations between four biological subtypes of breast cancer and the first sites of distant metastases. The dark-shaded (lower) parts of the columns depict the proportion of cancers that gave rise to more than one first metastatic site. The total number of metastatic sites is provided in each panel. ER, estrogen receptor; HER2, human epidermal growth factor receptor-2.
Figure 3
Figure 3
Association of eight breast tumor proteins with the first sites of distant metastases. The dark-shaded (lower) parts of the columns depict the proportion of cancers that gave rise to more than one first metastatic site. The total number of metastatic sites is provided in each panel. CK5, cytokeratin-5; COX2, cyclooxygenase 2; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; PgR, progesterone receptor.

Similar articles

Cited by

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2002;55:74–108. - PubMed
    1. Schopper D, de Wolf C. How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer. 2009;45:1916–1923. doi: 10.1016/j.ejca.2009.03.022. - DOI - PubMed
    1. Anderson WF, Reeves JE, Abdalla E, Berkel HJ. Outcome of patients with metastatic breast carcinoma treated a private medical oncology clinic. Cancer. 2000;88:95–107. doi: 10.1002/(SICI)1097-0142(20000101)88:1<95::AID-CNCR14>3.0.CO;2-P. - DOI - PubMed
    1. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E. Prognostic factors in 1038 women with metastatic breast cancer. Annals of Oncology. 2008;19:2012–2019. doi: 10.1093/annonc/mdn424. - DOI - PMC - PubMed
    1. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. doi: 10.1056/NEJMoa021967. - DOI - PubMed

Publication types

MeSH terms

Substances